Author details

Full Name

Richard J Milne

Affiliation

Health Outcomes Associates Limited and University of Auckland

ORCID

Career Start Year

1972

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34921351	CHEERS to 30 Years of PharmacoEconomics.	Pharmacoeconomics	2022
35072136	GA4GH: International policies and standards for data sharing across genomic research and healthcare.	Cell Genom	2021
31584720	Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand.	Br J Haematol	2020
30060070	Primary prevention of rheumatic fever in the 21st century: evaluation of a national programme.	Int J Epidemiol	2018
25662376	Hospital admissions for chronic obstructive pulmonary disease in New Zealand.	N Z Med J	2015
26370753	Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand.	N Z Med J	2015
24560197	Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?	Health Policy	2014
24968990	Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis.	Value Health	2014
24868083	Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.	BMJ	2014
23329425	Comparing subsidized access to medicines across payer systems.	Pharmacoeconomics	2013
22494452	Mortality and hospitalisation costs of rheumatic fever and rheumatic heart disease in New Zealand.	J Paediatr Child Health	2012
22494483	Incidence of acute rheumatic fever in New Zealand children and youth.	J Paediatr Child Health	2012
21777702	IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.	Contemp Clin Trials	2011
22237576	Response to PHARMAC on Access to new medicines in New Zealand compared to Australia.	N Z Med J	2011
22143849	Access to new medicines in New Zealand compared to Australia.	N Z Med J	2011
20593908	Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.	Paediatr Drugs	2010
20804222	Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand.	Appl Health Econ Health Policy	2010
19490550	Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.	Value Health	2009
19817522	Should rotavirus vaccines be included in the national immunization program of a small developed country?	Expert Rev Pharmacoecon Outcomes Res	2009
18391645	Quantifying the effect of age on short-term and long-term case fatality in 14,000 patients with incident cases of cardiovascular disease.	Eur J Cardiovasc Prev Rehabil	2008
16519549	Quality-of-life valuations of advanced breast cancer by New Zealand women.	Pharmacoeconomics	2006
15680460	Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.	Lancet	2005
16132078	Richard Milne responds to PHARMAC on discounting future health benefits and costs.	N Z Med J	2005
15886738	Valuing prevention: discounting health benefits and costs in New Zealand.	N Z Med J	2005
15164800	ISPOR's "Code of Ethics for Researchers": is it ethical?	Value Health	2004
15449631	Discounting health outcomes in economic evaluation: the ongoing debate.	Value Health	2004
12583966	Heart Protection Study.	Lancet	2003
14615805	Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factors.	N Z Med J	2003
14615804	Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.	N Z Med J	2003
12411381	New heart risk equations do not affect existing guidelines.	BMJ	2002
11127362	Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.	N Z Med J	2000
10623379	Communication of socioeconomic research findings.	Pharmacoeconomics	1999
10170463	A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.	Pharmacoeconomics	1997
10160114	Costs, innovation and efficiency in anti-infective therapy.	Pharmacoeconomics	1996
10147470	Evaluation of the pharmacoeconomic literature.	Pharmacoeconomics	1994
10146941	Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.	Pharmacoeconomics	1992
10147044	Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.	Pharmacoeconomics	1992
10147015	Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.	Pharmacoeconomics	1992
10146952	Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.	Pharmacoeconomics	1992
1711447	Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.	Drugs	1991
1769394	Habituation to repeated painful and non-painful cutaneous stimuli: a quantitative psychophysical study.	Exp Brain Res	1991
1715268	Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.	Drugs	1991
1711961	Ondansetron. Therapeutic use as an antiemetic.	Drugs	1991
1698268	Quaternary naloxone blocks morphine analgesia in spinal but not intact rats.	Neurosci Lett	1990
2207657	Behavioural modification of bulbospinal serotonergic inhibition and morphine analgesia.	Brain Res	1990
2357537	Hypercapnia depresses nociception: endogenous opioids implicated.	Brain Res	1990
2812847	Habituation to sham testing procedures modifies tail-flick latencies: effects on nociception rather than vasomotor tone.	Pain	1989
2765889	Behavioural tolerance to morphine analgesia is supraspinally mediated: a quantitative analysis of dose-response relationships.	Brain Res	1989
2717057	Repeated exposure to sham testing procedures reduces reflex withdrawal and hot-plate latencies: attenuation of tonic descending inhibition?	Neurosci Lett	1989
3384055	Reduction in perceived intensity of cutaneous stimuli during movement: a quantitative study.	Exp Brain Res	1988

1 - 50 of 62

Juan Pablo Domecq

Mayo Clinic

Career Start Year 2011

Number of shared co-authors 0

Mohammad Hassan Murad

Evidence Foundation

Career Start Year 2008

Number of shared co-authors 0

Michael Fralick

University of Toronto

Career Start Year 2007

Number of shared co-authors 0

Weihua Gao

Peking University Third Hospital.

Career Start Year 2006

Number of shared co-authors 0

Rickey E Carter

Mayo Clinic

Career Start Year 2004

Number of shared co-authors 0

Nicholas Mitsakakis

Institute of Health Policy Management and Evaluation, University of Toronto

Career Start Year 2003

Number of shared co-authors 0

Julie A Stoner

The University of Oklahoma Health Sciences Center

Career Start Year 1999

Number of shared co-authors 0

Andrew Walker

University of California San Diego

Career Start Year 1995

Number of shared co-authors 0

Hung-Mo Lin

Icahn School of Medicine at Mount Sinai

Career Start Year 1995

Number of shared co-authors 0

George Tomlinson

University Health Network

Career Start Year 1994

Number of shared co-authors 0

Darrell R Schroeder

Mayo Clinic College of Medicine and Science

Career Start Year 1994

Number of shared co-authors 0

Peter Martus

Eberhard Karls University of Tuebingen

Career Start Year 1993

Number of shared co-authors 0

Sally C Morton

Virginia Commonwealth University

Career Start Year 1993

Number of shared co-authors 0

Jonathan J Deeks

Institute of Applied Health Research, University of Birmingham

Career Start Year 1991

Number of shared co-authors 0

Daniel W Byrne

Vanderbilt University Medical Center

Career Start Year 1990

Number of shared co-authors 0

Jesse A Berlin

Rutgers University School of Public Health

Career Start Year 1988

Number of shared co-authors 0

Christopher M Frampton

University of Otago

Career Start Year 1986

Number of shared co-authors 1

Karen Byth

Westmead Hospital

Career Start Year 1983

Number of shared co-authors 1

Theodore G Ganiats

university of california san diego

Career Start Year 1983

Number of shared co-authors 1

Robert A Parker

Massachusetts General Hospital

Career Start Year 1982

Number of shared co-authors 0

Charles M Stein

Vanderbilt University School of Medicine

Career Start Year 1982

Number of shared co-authors 3

Dale F Kraemer

6 Department of Medical Informatics and Clinical Epidemiology.

Career Start Year 1981

Number of shared co-authors 0

Richard W Morris

School of Psychology and Sydney Medical School, The University of Sydney

Career Start Year 1979

Number of shared co-authors 2

David A Schoenfeld

Mass General Hospital

Career Start Year 1977

Number of shared co-authors 0

Stan N Finkelstein

University of Toronto

Career Start Year 1977

Number of shared co-authors 0

Alexander M Walker

Harvard T.H. Chan School of Public Health

Career Start Year 1975

Number of shared co-authors 0

Jane Garb

Weizmann Institute of Science

Career Start Year 1974

Number of shared co-authors 0

Brian L Strom

Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Career Start Year 1970

Number of shared co-authors 2

Richard L Byyny

Denver Health Medical Center, University of Colorado School of Medicine

Career Start Year 1969

Number of shared co-authors 0

row(s) 1 - 29 of 29

Ada Hamosh

Johns Hopkins University School of Medicine

Co-authored papers 1

Emilio Palumbo

The Barcelona Institute for Science and Technology

Co-authored papers 1

Lyndon Zass

University of Cape Town

Co-authored papers 1

Manuel Rueda

The Barcelona Institute of Science and Technology

Co-authored papers 1

Albert V Smith

University of Michigan School of Public Health ann arbor

Co-authored papers 1

David Glazer

Verily Life Sciences LLC

Co-authored papers 1

Jerome Kelleher

University of Oxford

Co-authored papers 1

Angel Pizarro

The Institute for Translational Medicine and Therapeutics, University of Pennsylvania

Co-authored papers 1

Michael J S Beauvais

McGill University

Co-authored papers 1

Anna Middleton

Kavli Centre for Ethics, University of Cambridge

Co-authored papers 1

Soichi Ogishima

Tohoku University Graduate School of Medicine

Co-authored papers 1

Helen Schuilenburg

European Bioinformatics Institute

Co-authored papers 1

Torsten Schwede

University of Basel

Co-authored papers 1

Zornitza Stark

Murdoch Children's Research Institute

Co-authored papers 1

Brian Walsh

Oregon Health & Science University

Co-authored papers 1

Rachele M Hendricks-Sturrup

Duke-Margolis Center for Health Policy

Co-authored papers 1

Monica C Munoz-Torres

University of Colorado Anschutz Medical Campus

Co-authored papers 1

Megan Doerr

Cleveland Clinic

Co-authored papers 1

Neerjah Skantharajah

Ontario Institute for Cancer Research

Co-authored papers 1

Robert M Davies

Wellcome Sanger Institute

Co-authored papers 1

Danielle Denisko

University of Toronto

Co-authored papers 1

Melissa A Haendel

American Medical Informatics Association, Oregon Health and Science University, Oregon State University, University of Colorado Anschutz Medical Campus, University of North Carolina at Chapel Hill, University of Wisconsin-Madison

Co-authored papers 1

Reece K Hart

Broad Institute of MIT and Harvard

Co-authored papers 1

Tristan Nelson

Genomic Medicine Institute

Co-authored papers 1

Debyani Chakravarty

Memorial Sloan Kettering Cancer Center

Co-authored papers 1

David Bernick

Broad Institute of MIT and Harvard